Argenx Se

argenx announces Annual General Meeting of Shareholders on May 6, 2026

Unnatural Products Raises $45 Million Series B Financing to Advance Macrocyclic Peptide Therapeutics

argenx to Present New Data at 2026 AAN Annual Meeting that Continue to Transform Patient Outcomes in MG and CIDP and Build Upon Strength of Pipeline

argenx Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update

argenx Announces Positive Topline Results from Phase 3 ADAPT OCULUS Trial of VYVGART in Ocular Myasthenia Gravis